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To Cilla, Anna and Hjalmar
4I. Abstract 
Intermittent claudication (IC) is caused by obstructive arterial lesions 
and is characterized by effort-induced pain in the lower extremity, 
limiting walking distance, and reduced health-related quality of life 
(HRQoL). The prevalence of IC is increasing due to the ageing of the 
population, and the consequences of the economic effects are a global 
problem. The walking impairment can be reduced by exercise. Despite 
the paucity of evidence regarding long-term benefit and cost-effective-
ness, invasive revascularization is also often performed. 
We wanted to investigate whether invasive treatment for IC is safe with 
regard to procedure-related limb loss, whether it is cost-effective, and 
whether it has long-term clinical benefit compared to exercise only.
The Swedvasc registry was used to identify all revascularizations per-
formed in Sweden for IC between 2008 and 2012. Amputations were 
captured using the National Patient Registry (Paper I). Cost-effective-
ness was analyzed in two prospective randomized trials, the IRONIC 
trial and a randomized trial investigating stenting of the superficial 
femoral artery in IC (papers II, III, and IV). The long-term clinical 
effect was analyzed in the IRONIC trial (paper III).
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We found a low rate of major amputations during the first year after 
revascularization for IC: 0.2% (Paper I). A liberal invasive treatment 
strategy was found to be more expensive than exercise advice only 
after two years of follow-up. Cost-effectiveness results were within the 
threshold of the Swedish national guidelines regarding willingness to 
pay (papers II and IV). Both the clinical benefit and the cost-effective-
ness of a liberal invasive treatment strategy that were found after two 
years of follow-up was lost at five years (paper III). 
In conclusion, invasive revascularization of patients with IC appears 
to be safe in terms of limb outcome within the first post-procedural 
year. A liberal invasive treatment strategy was cost-effective compared 
to exercise alone after two years of follow-up. No clinical benefit, nor 
cost-effectiveness compared to exercise remained after five years.
Future studies should aim at identifying IC subgroups that benefit the 
most from revascularization and exercise, respectively, in order to en-
hance the overall patient benefit from available treatment options.
Keywords: intermittent claudication, peripheral arterial disease, 
cost-effectiveness, invasive treatment, health-related quality of life 
6
7HENRIK DJERF
This thesis is based on the following studies, which are referred 
to in the text by their Roman numerals.
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ABI  Ankle-Brachial Index
BMT  Best Medical Therapy
CEAC    Cost-Effectiveness Acceptability Curve
CLTI   Chronic Limb-threatening ischemia
EQ-5D  EuroQol Five Dimensions
HRQoL  Health-Related Quality of Life 
IC   Intermittent Claudication
ICD   Intermittent Claudication Distance
ICER   Incremental Cost-Effectiveness Ratio (ICER)
MCS   Mental Component Summary
MI   Multiple Imputation
MWD   Maximum Walking Distance
PAD   Peripheral Arterial Disease
PCS   Physical Component Summary 
PTA   Percutaneous Transluminal Angioplasty
QALY   Quality-Adjusted Life Year 
RCT   Randomized Controlled Trial
SAP   Subintimal Angioplasty
SET   Supervised Exercise Therapy 
SFA   Superficial Femoral Artery
SF-36   Short Form 36
TEA   Thromboendarterectomy
6 MWD  Six-Minute Walk Distance test
III. Abbrevations
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1.1 What is intermittent claudication? 
Intermittent claudication (IC) is caused by obstructive atherosclerotic 
lesions in the aorta or in the arteries distal to the aortic bifurcation. At 
rest, the blood flow to the lower extremity muscles is sufficient. How-
ever, due to an increased need for oxygen and nutrients in the muscles 
during exercise, the blood flow to the leg muscles increases. The arteri-
al obstructions present in patients with IC then lead to an insufficient 
inflow of blood to the leg muscles, causing ischemic muscular pain that 
constrains the individual’s walking capacity. The pain is relieved by a 
short period of rest and returns when exercise is once again performed. 
Thus, the clinical definition of IC is: reproducible ischemic muscular 
pain in the lower extremity, induced by exercise and relieved with short 
periods of rest1.
The word claudication is derived from the Latin word “claudicare”, 
which means “to limp”. It comes from the name of the Roman emper-
or Claudius who could only walk short distances due to a limp.  
Although patients with IC do not limp, his name became the origin  
for the condition “Intermittent claudication”.
Introduction
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1.2 Intermittent claudication is a manifestation of 
peripheral arterial disease 
Intermittent claudication is the most common symptomatic manifesta-
tion of lower extremity arterial disease (LEAD), which is often referred 
to as peripheral arterial disease (PAD) even though the term “peripher-
al arterial diseases” also includes peripheral vessels that are not located 
in the lower extremities.
Most patients with PAD have no limb symptoms. This means that the 
arterial obstruction causes no symptoms at rest or during walking. The 
symptoms may, however, be masked due to other medical conditions.
Intermittent claudication is the most common clinical presentation 
of PAD. As mentioned earlier, the symptoms are reproducible ischemic 
muscular pain in the lower extremity, induced by exercise and relieved 
by short periods of rest.  
The most severe form of PAD is chronic limb-threatening ischemia 
(CLTI), which is a limb-threatening condition due to inadequate blood 
flow and insufficient supply of oxygen and nutrients to lower extrem-
ity tissues at rest. The clinical symptoms of CLTI are extremity pain at 
rest and/or the development of ulcers or tissue gangrene. Patients with 
CLTI have a considerably higher risk of both amputation and mortali-
ty than patients with IC2. 
The Rutherford and the Fontaine classifications are two classifica-
tions for PAD that are used in research. A formal assessment of IC ac-
cording to the Rutherford classification requires a treadmill test, which 
is mostly not performed in clinical practice.
1.3 Effects of peripheral arterial disease and the  
natural history for the patient
Patients at any stage of PAD have been shown to have a significantly 
increased risk of cardiovascular events and premature death3.  
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For patients with IC, the mortality rate has been reported to be two 
and a half times that of an age-matched population4.
The increased cardiovascular risk and increased risk of mortality is 
the most important threat for patients with IC.
The impairment in walking function and the resulting reduction in 
health-related quality of life (HRQoL)5 constitutes the second problem 
for the patient with IC6, even though most patients probably perceive 
this to be their key problem.
In contrast to the risk of CV events and death, the prognosis for the 
affected limb is relatively benign and loss of a limb is a rare outcome7. 
Deterioration in IC occurs in 25% of the patients, and 13% may 
undergo a major amputation within five years8, 9. Another study found 
cumulative 10-year risks of developing ischemic rest pain and ischemic 
ulcer of 30% and 23%, respectively10. Persistent smoking and diabetes 
may increase the risk of deterioration4, 10. 
1.4 Prevalence of peripheral arterial disease and its 
impact in the world
Peripheral arterial disease affects over 200 million people and is in-
creasing due to the ageing of the population11. 
The majority of people who are affected are asymptomatic regard-
ing lower limb symptoms. Intermittent claudication, which is the most 
common symptomatic presentation, has a prevalence of almost 7% 
in individuals over 60 years of age12 and affects 20-40 million people 
worldwide11.
Due to the growing number of people with PAD11 and the increas-
ing costs associated with it13, the consequences of IC for HRQoL and 
in economic terms constitute a global health problem.
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1.5 Risk factors
The main cause of arterial obstruction is atherosclerosis (development 
of plaques inside the arteries). The word atherosclerosis is derived from 
the Greek words athere (meaning gruel) and skleros (meaning hard)1.
Intermittent claudication is a symptomatic presentation of athero-
sclerotic disease, so the general risk factors for development of athero-
sclerosis disease also apply to IC. 
Smoking is one of the most prominent risk factors both for the de-
velopment of IC and for deterioration of IC to CLTI14. Diabetes is 
also strongly associated with both incidence of IC and progression to 
CLTI15, 16. Furthermore, hypertension and elevated cholesterol levels are 
also associated with the development of IC17.
Physical inactivity is an independent risk factor for cardiovascular and 
overall mortality18, and there is an association between risk factors for 
the metabolic syndrome and reduced peripheral circulation19. Patients 
with chronic kidney disease have an increased risk of developing 
PAD20.
Of the non-modifiable risk factors, age and non-white ethnicity have 
been found to be associated with an increased risk of PAD21. Women 
appear to be as affected as men12. People with low socioeconomic sta-
tus tend to have a higher prevalence of IC, mostly due to exposure to 
other risk factors such as smoking20.
1.6 Anatomy
The arteries to the lower extremity consist of the aorta and the ili-
ac vessels. Below the inguinal ligament, in the lower extremities, the 
vessels consist of the femoral arteries, the popliteal artery, the tibial 
arteries, and the peroneal artery. In the foot, the dorsalis pedis artery 
forms a foot arcade together with the posterior tibial artery. 
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1.7 Clinical diagnosis
Diagnosis of IC is done from clinical evaluation based on relevant pa-
tient history in combination with a physical examination.
The most common localization of the symptomatic presentation 
of muscle pain or fatigue is at the calf, but symptoms may also come 
from the thigh or buttocks. Intensification of exercise tempo such as 
climbing of stairs, walking uphill, or increased walking speed provokes 
symptoms more rapidly.
 
It is important to be aware of the possibility that other disease, which 
forces the patient to stop walking, may mask IC symptomatology. 
Examples of this would be cardiopulmonary diseases that impair the 
patient’s condition such as obstructive pulmonary disease or musculo-
skeletal or neurogenic diseases like spinal stenosis. 
The physical examination includes an objective hemodynamic assess-
ment of the peripheral perfusion using an ankle-brachial index (ABI). 
ABI is calculated by dividing the highest systolic blood pressure in the 
upper arms by the systolic blood pressure at ankle level. An index of 
0.9-1.4 would be considered normal8. 
One should be aware that ABI at rest can be normal in patients with 
IC, and if there is any uncertainty about the diagnosis, a treadmill test 
can be performed. The treadmill test is a useful tool to distinguish IC 
from other conditions with similar symptomatology6.
Treadmill testing enables the clinician to induce exercise stress and 
to measure the ABI before and after the exercise. The blood pressure 
at the ankle drops after exercise. A drop in ABI by more than 15-20% 
compared to the initial value verifies the diagnosis6. 
One should remember that for some patients (mainly those with 
diabetes or severe renal disease), the ABI may be falsely elevated. This 
is due to calcification of the arterial wall, which makes the blood vessel 
non-compressible. In these cases, additional testing is required for a 
PAD diagnosis6.
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Another possible origin of a false ABI would be if the patient has an 
arterial lesion in the subclavian or axillary artery, reducing the blood 
pressure to the arm.
Generally speaking, diagnosis of IC is based on clinical signs. Radiologi-
cal imaging is mainly performed to plan a revascularization strategy. 
1.8 Assessment of walking limitations and health- 
related quality of life in intermittent claudication
Objective assessment of walking capacity in patients with IC can be 
achieved in several ways. The most common way in clinical practice is 
to simply ask the patient about his/her walking capacity. This, however, 
is very unreliable and the assessment of distance is often inaccurate22, 23.
 
In the study setting, the treadmill test is a widely adopted option24 and 
has been used for decades. It offers the possibility of grading the walk-
ing capacity. Several different protocols are in use, and the treadmill 
test can be varied both regarding speed and inclination.
Treadmill tests are not always available, however, and corridor-based 
tests have been developed that may better reflect the patient’s daily walk-
ing ability25. One example is the six-minute walk distance test (6MWD), 
which encourages the patient to cover a distance of 100 feet (30.5 m) 
as many times as possible over 6 minutes. One should be aware that the 
results of 6MWD and the treadmill test may be different26. 
The objective measures of ABI and walking distance do not, howev-
er, correlate to daily functional status, mostly due to different needs 
of individual patients for walking capacity and to different lifestyles. 
To highlight the aspects of illness in individual patients, measures of 
health-related quality of life (HRQoL) are therefore used27. When mea-
suring HRQoL, both generic and disease-specific instruments can be 
used. A common strategy is to use both a generic and a condition- 
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specific instrument28. One well-established generic HRQoL instrument 
is the medical outcomes study Short Form 36 (SF-36). It has often been 
used in IC patients and has been validated in Sweden29, 30.
It includes 36 items covering different aspects of HRQoL, generating 
eight different domain scores (PF = physical functioning; RP = role 
physical; BP = bodily pain; GH = general health; VT = vitality; RE = 
role emotional; SF = social functioning; and MH = mental health).  
It also includes two summary measures, Physical Component Summary 
and Mental Component Summary. Possible domain scores range from 
0 to 100 (where 100 denotes the best HRQoL).
 
Another measure is the EuroQoL Five-dimension questionnaire, which 
was developed by the EuroQoL group31. It exists in versions with  
3- and 5-scale steps. For patients with IC, it is mostly used for 
health-economic studies.
One disease-specific HRQoL instrument for patients with PAD is 
the Vascular Quality of Life questionnaire (VascuQoL), which was 
developed by Morgan et al.32 and is recommended for IC patients28, 33. 
It consists of 25 items, subdivided into five domains: activities (eight 
items), symptoms (four items), pain (four items), emotional (seven 
items), and social (two items). Each question has a seven-stage re-
sponse scale. It generates five domain scores and a total score ranging 
from one to seven (where seven is the best HRQoL).
20
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The treatment of IC has two main objectives. The first objective is to 
reduce the risk of future cardiovascular events due to atherosclerosis 
and the second is to reduce lower limb symptoms. This necessitates a 
thorough approach including lifestyle changes, medical therapy, exer-
cise, and – if needed – invasive treatment. 
2.1 Reducing the risk of cardiovascular events
The first objective is to reduce the risk of future cardiovascular events. 
This requires lifestyle changes (smoking cessation, optimal diet, and 
increased physical activity) and pharmacological secondary preventive 
treatment6. There have, however, been reports that a substantial num-
ber of patients do not receive risk factor treatment as recommended in 
guidelines27, 34.
Smoking cessation is important to reduce the risk of cardiovascu-
lar events and also to reduce the risk of deterioration of IC6. Several 
studies have shown that statins provide improvements in the cardio-
vascular prognosis for patients with IC. As an extra benefit, statins 
have also been shown to improve pain-free and maximal walking 
distances in patients with IC35, 36. Anti-platelet therapy is recommended 
to reduce the risk of cardiovascular events in patients with PAD37. All 
patients with PAD should have control of hypertension, and hyperten-
sive patients should receive treatment to reduce cardiovascular events6. 
Diabetes is associated with progression to CLTI and increased risk of 
cardiovascular events, and must be treated15, 20. 
Treatment of IC: 
clinical considerations
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2.2 Reducing lower limb symptoms
The second objective is to improve HRQoL by reducing limb symp-
toms. Many of the strategies for reducing cardiovascular events con-
tribute to the second goal of reducing lower limb symptoms. Thus, the 
first objective acts as a foundation for the second objective.
Lower limb symptoms can be alleviated by exercise therapy and by 
invasive treatment (revascularization)6, 38. Regarding medications, sta-
tin has led to improved walking distances and is recommended in ESC 
guidelines6. Some other medications, mainly cilostazol, may have  
a positive effect on lower limb symptoms but have not been recom-
mended in ESC guidelines.
2.2A Exercise
Exercise training is a cornerstone in the treatment of lower limb symp-
toms for IC. Supervised exercise therapy (SET) especially, where the pa-
tients receive training guidance from healthcare personnel in a health-
care facility, is often recommended as first-line treatment 6, 39. However, 
there is often no reimbursement for SET and it is not available to most 
patients40, in which case unsupervised exercise is recommended6. In 
addition, studies have mainly compared the efficacy for short periods 
of time41. Concerns have been raised regarding long-term adherence to 
SET, so it is uncertain whether the superior effects of SET compared to 
unsupervised exercise are maintained for long periods of time42.
A recent meta-analysis has also shown that home-based structured 
exercise therapy (HSET) – where patients perform the exercise at home 
but receive continuous feedback from healthcare personnel – may 
improve walking capacity43. The long-term effects of HSET still remain 
to be investigated.
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2.2B Invasive treatment: general considerations
Invasive treatment can be performed by endovascular surgery or open 
surgery. 
Endovascular surgery, a minimally invasive approach, is mostly 
conducted under local anaesthesia in an angio suite.  A majority of 
the procedures performed for IC in Sweden are undertaken via the 
endovascular route2. The approach is percutaneous, and by using the 
Seldinger technique an introducer is inserted into the vessel either with 
or without ultrasound guidance.
From the introducer, percutaneous transluminal angioplasty (PTA) 
of the atherosclerotic lesion can be performed with or without stenting 
of the artery.
Open surgery is performed in an operating theatre. In open surgery, the 
arteries explored are fully visible in the operational field by incision of 
the skin and by dissecting the target arteries free from the surrounding 
tissues. A minority of the IC procedures are performed by open sur-
gery2.
One example of open surgical technique is thrombendarectomy. For 
lower extremity arterial disease, this procedure is often performed in 
the common femoral artery. This method consists of opening the vessel 
and removing the atherosclerotic lesion, followed by suture or patch 
closure of the artery. 
Another example is bypass surgery, where the surgeon bypasses the 
arterial occlusion with synthetic or autologous bypass material. The 
most commonly used autologous material is the great saphenous vein. 
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2.2C Invasive treatment: evidence
Invasive treatment is offered to patients to relieve lower limb symptoms6, 44.
Randomized studies comparing invasive treatment with exercise 
have often applied selective inclusion criterias, and there has been het-
erogeneity between the studies regarding the type of invasive modality 
performed, anatomical segments, type of concomitant exercise therapy, 
severity of IC, and primary endpoints – which has made it difficult 
to draw any general conclusions regarding invasive treatment. A few 
randomized studies (Nordanstig et al.45, Gelin et al.46, and the IRON-
IC study47, 48) have included both the aorto-iliac and femoro-popliteal 
segments and both endovascular and open surgery, when comparing an 
invasive strategy with a non-invasive strategy.
A number of randomized studies have shown some benefit of invasive 
treatment up to a year over exercise; for example, Gelin et al.46 found 
moderate benefits in walking capacity and HRQoL with open and 
endovascular treatment compared to SET49, Lundgren et al. showed 
benefit of open vascular surgery compared to SET50, and Fakhry et al.51 
compared SET alone with combined endovascular treatment and SET, 
and found positive results regarding walking distances and HRQoL 
when invasive treatment was included. All studies included aorto-iliac 
and femoro-popliteal segments. 
Superiority of invasive treatment compared to exercise in aorto-iliac 
and femoro-popliteal segments with two years of follow-up has been 
found in randomized studies by the IRONIC study48, and by Green-
halgh et al., who showed some benefit of PTA as adjuvant treatment to 
SET in mild to moderate IC. Nylaende et al. also found some benefit of 
PTA over conservative treatment after two years52.
In a study by Lindgren et al.53, primary stenting of SFA in addition to 
exercise advice led to a durable increase in HRQoL after two years of 
follow-up compared to exercise advice alone.
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However, several studies have not shown any benefit of invasive treat-
ment compared to exercise.
Spronk et al. showed similar HRQoL results for endovascular treat-
ment in aorto-iliac and femoro-popliteal segments and for supervised 
exercise54 after one year of follow-up.
Mazari et al. also showed comparable effects after one year of fol-
low-up between three treatment arms, SET vs. PTA vs. SET and PTA 
together, for femoro-popliteal disease.
Whyman et al. did not find any benefit of PTA, in terms of HRQoL or 
walking capacity, at two-year follow-up 55.
Murphy et al. found similar effects of invasive treatment and exercise 
after 18 months when comparing between three treatment arms, stent 
treatment and BMT vs. SET and BMT vs. BMT alone, for moderate to 
severe claudication due to aorto-iliac lesions56. 
An earlier study by Nordanstig et al. showed no improvement in walk-
ing capacity after two years of follow-up after invasive treatment with 
endovascular or open surgery rather than exercise advice alone45.
Furthermore, a systematic review by Malgor et al. showed benefits 
from both invasive treatment and exercise but the authors could not 
conclude that any particular treatment approach was superior.
A meta-analysis by Klaphake et al.57 could not distinguish any favour-
able effects in maximum walking distance or HRQoL when comparing 
endovascular treatment and SET with SET alone or endovascular treat-
ment alone. In contrast to this, another meta-analysis from Saratsis 
et al.58 found benefits in terms of walking distance and HRQoL with 
combined treatment compared to PTA or SET alone after one year of 
follow-up.
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In 2018, a Cochrane systematic review by Fakhry et al. summarizing 
the added effects of endovascular treatment found no significant bene-
fit compared to SET, but the authors suggested that one should consid-
er a combination of endovascular treatment and SET.
Thus, studies have mainly been performed with one- or two-year 
follow-up, and the results have varied regarding the benefit of invasive 
treatment. 
Randomized studies by Fakhry and Mazari, with 7 years and 5 years 
of follow-up, respectively, have not been able to show any long-term 
superiority compared to SET59, 60. Fakhry et al., who compared SET 
and endovascular revascularization in both the iliac and femoro-pop-
liteal segments, showed comparable effects after 7 years for SET and 
endovascular revascularization regarding quality of life and functional 
performance. Mazari et al., who compared PTA vs. SET vs. combined 
treatment for femoro-politeal disease found similar effects after 5 years 
in all three groups. 
Thus, there have been no randomized studies demonstrating any bene-
fits of invasive treatment over non-invasive treatment beyond the first 
two years. 
When treating patients invasively, one must also consider the risk 
of complications. The most feared complication is the risk of am-
putation61. One study found that an early revascularization strategy 
appeared to increase the long-term rate of amputation compared to 
patients initially treated with a non-invasive approach, at five-year 
follow-up62.
Since endovascular treatment is constantly evolving, some vascular 
centres adopted new technical solutions during the course of this thesis 
work. One new solution is atherectomy, where the plaque is removed 
using endovascular techniques. However, one study showed high rates 
of amputation after one year63 and another study showed a high rate of 
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long-term adverse events with atherectomy compared to stent64. One 
of the most prominent new solutions during the past decade have been 
the use of drug-coated stents and balloons that were developed to mit-
igate restenosis after endovascular treatment. However, in December 
2018, Katsanos et al. presented a meta-analysis signalling an increased 
risk of death following the use of paclitaxel-coated devices65. Further 
studies will hopefully provide evidence regarding whether this claim is 
or is not true.
28
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3.1 Reasons for economic considerations
The costs of healthcare are increasing in Sweden and in many other 
western countries66. In Sweden, the costs for PAD in 2005 were es-
timated to be more than a billion SEK, excluding costs for primary 
healthcare, municipal healthcare, and social services. Most of these 
costs were derived from in-patient treatment at hospitals27.
With the increasing number of patients with PAD, the economic 
impact on healthcare resources is expected to be substantial13.
 
Since healthcare resources are limited, the use of economic evaluations 
in healthcare settings has increased considerably. Economic evaluations 
alongside clinical trials are an important resource to help decision mak-
ers when deciding which medical technologies should receive funding.
Treatment of IC:
economic considerations
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Economic analysis can be done from a payer/healthcare standpoint, 
where one only considers the cost to the healthcare provider, or from a 
broader perspective where one estimates the wider economic effects of 
the treatment on society.
It is important to remember that health-economic evaluations are 
meant to give support for decision making. The decision maker has 
many other aspects to consider that the evaluation itself may not have 
considered – considerations such as the severity of the disease and pos-
sible effects on society, if these have not been included in the analysis. 
3.2 Assessment of the cost-effectiveness of invasive 
treatment for intermittent claudication
In a cost-effectiveness analysis, the treatment under study is compared 
with alternative course(s) of action that are clinically relevant. By 
considering both the resources used (the costs) and the clinical conse-
quences of the treatments (the effects), one can perform a cost-effec-
tiveness analysis. 
Assessing health-related quality of life in  
cost-effectiveness analysis 
There are different measures of health-related quality of life in eco-
nomic analysis. One widely used measure is QALY (Quality-Adjusted 
Life Year). Another example is DALY (Disability-Adjusted Life Year67).  
A recently proposed new alternative is Health Years in Total (HYT)68.
 
Different methods have been developed for evaluating health states 
and creating HRQoL instruments to be used in clinical studies for 
health-economic evaluations.
Evaluation of health states can be achieved by asking people to 
evaluate a health state that is described to them, or to ask them to  
evaluate their own state of health. 
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There are different views concerning the best way to evaluate health 
states.
Arguments favouring evaluations from the general public would be, 
for example, that tax payers are entitled to evaluate heath states used 
in health-economic evaluations. Arguments favouring the argument 
that patients should evaluate the health states is that they have expe-
rience of the actual disease. It is important to know what preferences 
have been used when using a prescored HRQoL instrument, since the 
evaluations by patients differ from those of the general public69.
In cost-effectiveness analysis, we want to capture both the health 
aspect and the time aspect. QALY is a measure that combines both 
quality of life and quantity of life lived. One QALY can be viewed as 
one year lived in the best possible health state. It is often recommended 
as an effectiveness measure in health-economic evaluations70.
The quality of life component (qalyweight) is measured with an 
index where 1 is the best possible health state and 0 is assumed to be 
equivalent to death. Negative values are theoretically possible.
Three main direct methods have been used to produce QALY weights:
1. The first method, the rating scale, is often referred to as the visual 
analogue scale (VAS). In this method, the responders indicate where 
they would locate a specific health state on a ruler scale.
  
2. The standard gamble method makes people choose between differ-
ent health state alternatives.
 
3. The third method, and the one used in our analysis, is the time trade-
off (TTO) method. It was developed by Torrance in the 1970s and 
is often considered to be easier than the standard gamble method. It 
requires that people choose between different options of health states 
combined with a time preference. It aims at finding a point of indiffer-
ence between time spent with a reduced health state compared to the 
time spent with a full health state71.
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In applied cost-effectiveness studies, indirect prescored intruments are 
usually used to assess QALY weights. One of the most frequently used 
prescored instruments in health-economic evaluations is the EuroQol-5 
dimensions (EQ-5D) instrument, developed by the EuroQol group. 
It contains five domains: mobility, self-care, usual activities, pain/dis-
comfort, and anxiety/depression. It exists in a three-level version and 
a five-level version. The original three-level value set was developed by 
Dolan by use of TTO responses from a sample of adults in the general 
population in England72. Examples of other instruments used to create 
QALYs are SF-6D and HUI.
An advantage of QALYs is that they enable comparisons across all 
areas of healthcare.
A disadvantage with QALYs is that a gain in QALYs for a patient who 
has more severe illness might be worth much more than for a patient 
with less severe illness. QALYs may also discriminate against older 
people or people who already have a severe disease, since they have a 
shorter life expectancy and do not have the possibility of accumulating 
QALYs. 
Collection of cost data
Cost data can be retrieved from different cost registries. The benefit of 
using hospitals’ cost systems is that it is possible to accumulate pa-
tient-specific use of resources and to capture the variations in costs be-
tween patients that exist in clinical praxis. Retrieval of cost data can be 
time- and resource-consuming. It is therefore important to determine 
how precise the costs need to be in a study. The most precise level can 
be referred to as “micro-costing”, which identifies each component of 
resource use (such as laboratory tests and drugs). It is easier to identify 
small cost components if the economic evaluation is undertaken along-
side a prospective clinical study73.
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Comparative assessments in cost-effectiveness analysis
By comparing all the QALYs gained between treatments and the costs 
associated with the treatment, one can calculate the difference in cost 
per QALY and the result is referred to as the incremental cost-
effectiveness ratio (ICER). 
ICER =
(Effect A − Effect B)
(Cost A − Cost B)
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As can be seen in the cost-effectiveness plane, treatments in the north-
west quadrant are less effective and more expensive, relative to the 
comparator, just as treatments are more effective and less expensive in 
the south-east quadrant. In these cases, the decision maker gets a clear 
result that is easy to act on. Often however, the incremental effective-
ness and costs create a result that is situated in the north-east quadrant 
(where the treatment is more effective but costs more) or in the south-
west quadrant (where the treatment is less costly but also less effective).  
An illustrative way of graphically representing the results is the cost-ef-
fectiveness plane. The incremental effectiveness of the treatment versus 
the comparator is represented on the x-axis and the incremental cost 
versus the comparator is represented on the y-axis.
Treatment less 
effective and 
more costly
Incremental costs
Incremental  
effects
Treatment less 
effective and 
less costly
Treatment more 
effective and more 
costly
Treatment more 
effective and  
less costly
south-west  
quadrant
north-west  
quadrant
south-east 
quadrant
north-east 
quadrant
Figure 1.
Cost-effectiveness plane
35HENRIK DJERF
Under these circumstances, one has to decide if the health gain is worth 
the additional costs (or if the costs saving is worth the loss in health). 
The level of acceptance of how much money can be spent for a benefit 
in health varies depending on the country and the severity of the dis-
ease. This is often referred to as the maximum accepted level of public 
willingness to pay. 
In Sweden, the National Board of Health and Welfare has set a thres-
hold of 500,000 SEK/QALY to be considered expensive.
Unfortunately, it is not clear why these specific thresholds are recom-
mended. Alternatively, the Swedish Dental and Pharmaceutical agency 
provides recommendations on which pharmacotherapies should re-
ceive public funding. An analysis of their recommendations has shown 
that for a relatively benign disease like IC, there is a higher acceptance 
limit of 700,000 SEK/QALY75.
Classification  Threshold
Low    Below 100,000 SEK/QALY
Moderate  100,000–499,999 SEK/QALY
High   500,000–1,000,000 SEK/QALY
Very high  Above 1,000,000 SEK/QALY
Table 1.
Guidelines according to the Swedish National Board of Health and 
Welfare74.
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Uncertainty in cost-effectiveness analysis
In all cost-effectiveness analyses alongside clinical trials, there will be 
uncertainties regarding the results.
The uncertainty of the data input in the study is called “parameter 
uncertainty”. The impact of this uncertainty of the result can be inves-
tigated by sensitivity analyses, in which the data parameters are varied. 
Sensitivity analysis with non-parametric bootstrapping means that new 
datasets are created with sampling with replacements from the original 
data, and a new result is obtained. This can, for example, be performed 
1,000 times and we then get 1,000 different cost-effectiveness results. 
The result can be plotted in a cost-effectiveness plane (scatter plot), 
which is a good way to visually analyze the results. 
Figure 2.
Scatterplot
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The uncertainties when analyzing the results can also be expressed in 
relation to thresholds regarding willingness to pay for a QALY. By con-
structing a cost-effectiveness acceptability curve (CEAC), one can see 
the probability of a treatment being considered cost-effective at var-
ious thresholds. For example, at a willingnes to pay of 500,000 SEK, 
we simply calculate how many of the bootstrap results are below this 
value. This process is then repeated for different threshold values. 
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Cost-effectiveness acceptability curve - CEAC
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Dealing with missing data
Investigation whether missing data could have an important impact on 
the results of the cost-effectiveness analysis can be achieved in several 
ways. Imputation is a method that replaces missing values with esti-
mated values. In multiple imputation (MI), data are drawn into repeat-
ed datasets from the original data to fill in the missing data76, 77.
The vehicle for cost-effectiveness analysis: trial-based  
vs. modelling based
Modelling analysis such as, for example, Markov modelling is a useful 
tool when effects or costs are expected to continue beyond the time 
limit of the cost-effectiveness analysis in a study. It is also useful when 
we lack long-term clinical data, when RCTs only capture a proportion 
of the patients treated in clinical reality, and when randomized trial are 
not possible for example for ethical reasons or due to unreasonable 
costs associated with implementation of a study. 
Modelling analysis and cost-effectiveness analysis alongside RCTs can 
complement each other in providing evidence for decision making77.
3.3 Economic evidence regarding invasive treatment 
for intermittent claudication 
There have been few cost-effectiveness analyses alongside randomized 
trials in IC comparing invasive treatment against exercise. For one-
year analysis comparing aorto-iliac and femoro-popliteal endovascular 
treatment against SET, Spronk et al.78 indicated that endovascular 
revascularization cost more than the accepted public willingness to pay 
when a threshold of €50,000 was used. Mazari (2013) compared PTA 
vs. SET vs. combined treatment for femoro-popliteal lesions and they 
concluded that SET provided similar gains in QALYs (compared to the 
other treatments), and being the least costly alternative SET was also 
the most cost-effective option79.
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In the setting of a five-year horizon and by using Markov modelling 
approaches, Reynolds et al. compared stenting for aorto-iliac lesions 
with SET, and found that stenting had an ICER of $122,600 per QALY 
gained compared to SET80. Van den Houten et al. compared endovas-
cular revascularization with SET and found that invasive treatment 
had an additional cost of €91,600 per QALY gained compared to SET, 
and they concluded that SET was the most cost-effective option81. 
An older study with Markov modelling, by de Vries et al., suggested 
that angioplasty had an acceptable cost of $38,000 per QALY gained 
compared to execise alone, but that open bypass surgery had an addi-
tional cost of $311,000 per QALY gained compared to exercise82.
As previously mentioned, SET is often not available and unsupervised 
exercise is often the non-invasive treatment option offered to patients. 
The few cost-effectiveness analyses alongside randomized studies have 
had SET as the non-invasive treatment option.
Thus, in terms of cost-effectiveness studies alongside randomized stud-
ies, a comparison between the real-world alternatives (invasive treat-
ment and unsupervised exercise) is lacking.
Furthermore, there has been a lack of cost-effectiveness studies 
alongside randomized trials with a follow-up beyond one year for inva-
sive revascularization vs. exercise treatment.
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The aims of the work described in this thesis regarding invasive treat-
ment of IC were as follows:
• To investigate the risk of major amputation attributable to lower 
limb revascularization for IC (Paper I).
• To investigate the cost-effectiveness of a liberal invasive strategy 
in addition to exercise therapy advise and best medical treatment 
compared to exercise therapy advice and best medical treatment 
only (Paper II, III and IV).
• To investigate the long-term clinical benefit of a liberal invasive 
strategy in addition to exercise therapy advice and best medical 
treatment compared to exercise therapy advice and best medical 
treatment only (Paper III).
Aims
42
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5.1 Ethics
All the studies in the thesis had ethical applications and approvals.
Study I. Regional Ethical Board, Gothenburg: Dnr 873-14
Studies II and III. Regional Ethical Board, Gothenburg: Dnr 501-09
Study IV. Regional Ethical Board, Lund: Dnr 2016/827
Ethical consideration.
One might consider it to be difficult to randomize people between 
invasive treatment and non-invasive treatment (papers II, III, and 
IV). Invasive treatment entails risks for the patient. However, it has 
been shown that patients with IC tend to take risks in order to receive 
help61. Patients randomized to revascularization in a study may under-
go the invasive procedure before the non-invasive approach has been 
adequately tested. In such instances, the revascularization – and the 
risks and costs entailed – may be unnecessary. On the other hand, one 
can argue that withholding invasive treatment from a patient who has 
been randomized to non-invasive treatment may unnecessary prolong 
the patient’s lower limb symptoms and reduced HRQoL.
Patients and methods
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5.2 Patients and study design
The study designs of the four papers are summarized in Table 2.
Table 2.
Paper l
Paper ll
Paper lll
Paper lV
n = 5,860
n = 158
n = 158
n = 100
Design Patients Endpoints
Major amputation 
Incremental cost- 
effectiveness ratio 
HRQoL
Walking distance
Incremental cost- 
effectiveness ratio 
Incremental cost- 
effectiveness ratio 
Retrospective national cohort study
Data from the Swedvasc registry,  
the National Patient Registry, and 
medical journals
Single-centre, randomized  
controlled trial
Invasive treatment vs.  
non-invasive treatment
Single-centre, randomized  
controlled trial
Invasive treatment vs.  
non-invasive treatment
Randomized controlled  
multi-centre trial
Primary stenting of the superficial 
femoral artery vs. non-invasive treat-
ment
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5.3 Study I
This was a retrospective study with data from the Swedvasc registry 
and the National Patient Registry with complementary analysis of 
medical records.
The Swedvasc registry gathers data regarding vascular surgical proce-
dures, i.e. both open and endovascular procedures, and follow-up data 
for a year. All vascular surgical centres report to the registry83.
The National Patient Registry (NPR) has national coverage because it 
is mandatory for hospitals to report to this registry. It contains infor-
mation regarding diagnoses and procedural codes including above-an-
kle amputation codes.
Patients aged 50 years or more who underwent revascularization for 
IC between May 2008 and December 2012 in Sweden were identified 
from the Swedvasc registry. The start of this study period was chosen in 
order to facilitate the extraction of data due to the fact that the dataset 
of Swedvasc was redesigned in May 2008. Since the NPR is updated 
once a year and the work began in 2015, the follow-up to 31 Decem-
ber 2013 was the maximum time duration that it was possible  to 
receive available updates.
 
With a time limit of 31 December 2013 when extracting data from the 
NPR, all patients had one year of follow-up after invasive treatment. 
Data on major (i.e. above-ankle) amputations were extracted from the 
NPR and cross-matched with data from the Swedvasc registry. 
In cases of uncertainty regarding amputation levels or laterality, the 
medical record was reviewed on site at the hospital.
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In the next step, requests were made for medical records of patients 
with an invasive procedure and a subsequent ipsilateral amputation. 
In-depth analysis of the medical records was carried out at Sahlgrenska 
University Hospital. 
The primary outcome, procedure-related major amputation, was de-
fined as ipsilateral major amputation within one year after the revascu-
larization procedure. 
Figure 4.
Revascularized patients with  
intermittent claudication in the  
Swedvasc 2008-2012
Proportion of revascularized IC  
patients amputated following  
revascularization
Limited chart review at participating 
vascular centers. In cases in which 
there were uncertain data regarding 
an amputation event in the National 
Patient Registry.
Data on major amputa-
tion from the National 
Patient Registry
In-depth medical chart review 
at research center. In order  
to investigate the risk of  
procedure-related major  
amputation.
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5.4 Studies II and III
The IRONIC trial (Invasive Revascularization or Not in Intermittent 
Claudication) was an open-label, prospective randomized trial compar-
ing a liberal invasive treatment strategy with a non-invasive treatment 
strategy. It was performed at Sahlgrenska University Hospital. 
Patients with established and stable (more than 6 months) mild-to-se-
vere IC and duplex verified stenosis or occlusion in the aorto-iliac and/
or femoro-popliteal segment were recruited at Sahlgrenska University 
Hospital. The patients were randomized either to invasive treatment 
in addition to best medical treatment and exercise therapy or to best 
medical treatment and exercise therapy alone84.
Exclusion criteria were being aged > 80 years, having very severe or 
very mild IC, being unable to understand the instructions in Swedish, 
having more than one previously failed ipsilateral invasive treatment, 
and having ultrasound findings that indicated invasive treatment below 
the tibioperoneal trunk. The remaining patients who provided both 
verbal and written consent were enrolled.
After randomization, both study groups received medical management 
including secondary pharmacotherapy (anti-platelet and lipidlower-
ing therapy) and a voluntary smoking cessation programme. Diabetes 
and hypertension were treated according to Swedish guidelines48. All 
patients were offered cilostazol treatment. Both groups received verbal 
and written information on PAD, which also contained advice on exer-
cise therapy sessions for at least 30 min at least three times a week.
For the invasive group, the Trans-Atlantic Society Consensus 
(TASC) II recommendations8 were practised and TASC II A-C had 
endovascular treatment and TASC D had open surgical treatment both 
for the aorto-iliac segment and the femoro-popliteal segment. 
Both study groups had follow-up at 3, 6, 12, 24, and 60 months 
either by a vascular research nurse or a vascular surgeon. At follow-up, 
adherence to exercise advice was verified. Patients who underwent an 
invasive procedure had an additional follow-up after one month. 
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Costs were retrieved directly from the hospital’s cost-per-patient 
systems, which enabled cost comparisons between treatment arms. 
The following resource use items were identified: accumulated costs 
from the hospital’s cost-per-patient system concerning in-patient and 
out-patient visits. The costs for healthcare personnel comprised the 
full wage cost (included costs for social security). Patient-specific costs 
for primary and secondary surgical and endovascular procedures were 
identified based on the price per minute according to the hospital’s 
cost-per-patient system. Accumulated costs for postoperative care; 
costs of medications during surgery; and costs of anaesthetic proce-
dures, further diagnostic procedures at the radiology department and 
the clinical physiology department, blood transfusions, and tests at the 
clinical chemistry and bacteriology laboratories, were retrieved.
To ensure the robustness of cost data, an economist with experience 
of the hospital’s cost-per-patient system manually cross-checked the 
economic system with the corresponding different clinical entries, pro-
cedures, and hospital stays. 
The primary outcome measure for the study was change in HRQoL as 
assessed with the Short Form 36 (SF-36). 
Supporting endpoints were changes in HRQoL measured with Vas-
cuQoL, a PAD-specific questionnaire, walking distances by treadmill 
testing, and a cost-effectiveness analysis from the EQ-5D-3L question-
naire.
For the cost-effectiveness analysis, the EQ-5D-3L questionnaire was 
used to calculate quality-adjusted life years (QALYs). In-patient and 
out-patient costs were obtained during follow-up and cost-effectiveness 
was assessed as the cost per QALY gained, expressed as the incremen-
tal cost-effectiveness ratio (ICER). The main cost-effectiveness analysis 
was performed from an ITT standpoint. Both costs and QALYs were 
calculated based on a three per cent annual discount rate85. Regression 
analysis was used to adjust for the difference between groups in base-
line QALY weight86. The economic evaluation was performed from a 
payer/healthcare point of view.
49HENRIK DJERF
5.5 Study IV
IC is commonly caused by lesions in the superficial femoral artery 
(SFA), and endovascular treatment is a frequently performed treatment 
strategy87.
Patients were enrolled in an open-label, controlled randomized 
multi-centre study involving seven hospitals in Sweden. Patients were 
randomized either to primary stenting and exercise advice and best 
medical treatment or to non-invasive treatment with exercise advice 
and best medical treatment alone.
Inclusion criteria were established and stable IC (more than 6 
months), severity Fontaine IIB and walking capacity of less than 500 
metres by the treadmill test and with a verified de novo or restenotic 
SFA stenosis or occlusion. 
Exclusion criteria were age less than 18 years, no patent popliteal 
artery, less than one patent tibial artery, femoro-popliteal aneurysm, 
target artery diameter less than 4 mm, previous stent treatment in the 
femoro-popliteal artery, or reduced inflow to SFA. The lower boundary 
for the lesion had to be 3 cm above the patella. In addition, patients 
with earlier invasive treatment within three months of study inclusion, 
haemorrhagic stroke in the previous three months, earlier participation 
in any other clinical trial, or a life expectancy of less than two years 
were excluded.
After randomization, both study groups received medical treatment 
including secondary pharmacotherapy (anti-platelet and lipid lowering 
therapy) and a voluntary smoking cessation programme. Hypertension 
was treated according to Swedish guidelines. Stented patients were 
treated with dual anti-platelet for three months.
Both groups had follow-up at 1, 6 ,12, and 24 months. 
Costs for all patients treated in Skåne were obtained from the Region 
Skåne Healthcare Database (RSVD). The RSVD includes accumulated 
costs for in- and out-patient visits, including primary and secondary 
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revascularization procedures, anaesthetic procedures, postoperative 
care, drugs given during surgery and postoperative care, tests at the 
bacteriology and clinical chemistry laboratories, and diagnostic proce-
dures at the clinical physiology and radiology departments. The costs 
for healthcare personnel comprised the full wage cost (included costs 
for social security). 
To ensure the robustness of cost data, such data retrieved from RSVD 
were manually cross-checked with the corresponding medical records 
(procedures and in- and out-patient visits).
Cost data for the remaining patients (outside of Skåne) were not 
retrieved and were excluded from the analysis.
For the cost-effectiveness analysis, the EQ-5D-3L questionnaire was 
used to calculate QALYs.
The cost-effectiveness was assessed as the cost per QALY gained and 
expressed as the incremental cost-effectiveness ratio (ICER). The main 
cost-effectiveness analysis was performed from an ITT standpoint. 
Both costs and QALYs were calculated based on a three per cent 
annual discount rate85. Regression analysis was used to adjust for the 
difference between groups in baseline QALY weight. The economic 
evaluation was performed from a payer/healthcare point of view. In oc-
casional cases of loss of EQ-5D data, linear extrapolation was performed 
and the patient was included in the complete case analysis (CCA).  
5.6 Statistics
Data management and statistical analysis were done using Microsoft 
Excel version 16.16.18; SPSS version 25.0 (IBM Corp., Armonk, NY); 
and Stata version 15.1 (StataCorp, College Station, TX).
Descriptive statistics for baseline data were presented as mean ± 
standard deviation (SD). Student’s t-test was used for two-group com-
parisons of means, and Fisher’s exact test or Chi-square test was used 
for dichotomous variables.
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Regarding HRQoL outcomes (paper III), Student t-tests were used for 
inter-group comparisons of normally distributed continuous variables 
and the Mann-Whitney U-test was used for skewed distributions. The 
size of HRQoL change (effect size) was derived from the difference in 
mean values between baseline and follow-up divided by the SD at base-
line. Cohen criteria for clarifying effect size were used (small, 0.2–0.5; 
moderate, 0.5–0.8; and large, over 0.8) Significance was assumed at  
p < 0.05.
In our studies, the basis of the HRQoL outcomes and also of the 
cost-effectiveness outcome was the intention-to-treat (ITT) analysis 
(Papers II, III, and IV). In this analysis, the data were analyzed based 
on the initial treatment allocation regardless of whether the patient 
received the allocated treatment during the study period. 
In Study II, we also performed an “as treated” analysis where the data 
were analyzed based on the actual treatment that was given to the pa-
tient (regardless of which allocation group he/she belonged to) (Paper II).
In Paper III, we performed a complementary per-protocol analysis, 
which only analyzed the patients who had received the allocated treat-
ment. 
In the cost-effectiveness analysis, QALYs and costs were treated 
as continuous variables and differences in means between treatment 
groups were analyzed. Sampling uncertainty was evaluated using 
non-parametric bootstrapping with 1,000 bootstrap resamples. 
Where there were missing QALY weight data, we used multiple 
imputation (MI) methods (Papers III and IV)76.
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6.1 Study I
Altogether, 5,860 patients were revascularized for IC between May 
2008 and December 2012. Of these, we found that 5,748 patients had 
not suffered any major amputation after cross-checking with data from 
the NPR and limited medical record reviews at participating vascular 
centres in cases of uncertainty. 
For three additional patients, there was uncertainty regarding the later-
ality of the amputation in the NPR, and the medical records could not 
be obtained. For the remaining 109 patients who had suffered a major 
amputation after revascularization for IC, in-depth medical chart anal-
ysis was performed regarding the primary outcome, which was defined 
as major amputation within the first post-procedural year.
The chart analysis showed that 51 patients had been revascularized for 
CLTI, two had been revascularized for indications other than PAD, two 
had had no or minor amputation, one had not been revascularized, 17 
had duplicate registrations, and 17 had had an amputation more than 
one year after revascularization. Only nine patients had undergone 
amputation within a year after invasive treatment for IC, giving an 
amputation rate of 0.2% (9/5,860). 
Results
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Figure 5.
5 860 revascularized patients with  
intermittent claudication in the  
Swedvasc 2008-2012
Patients with major  
amputation > 1 year after  
revascularization for IC n = 27
Patients with major  
amputation < 1 year after  
revascularization for IC n = 9
Medical charts could  
not be obtained n = 3
No major amputation  
n = 5 748
Duplicate  
registrations n = 17
Patients with  
CLTI n = 51
Revascularization for 
indication other than 
PAD n = 2
Not revascularized  
n = 1
Minor or no  
amputation n = 2
The nine patients who had been amputated within the first post-pro-
cedural year had had different invasive IC procedures: three endovas-
cular procedures, three hybrid procedures, and three open surgical 
bypasses. The majority (eight of the nine patients) had undergone 
procedures involving the femoro-popliteal segment whereas only one 
patient had a solely iliac procedure. Eight of the nine patients had onset 
of new symptoms within 2 months, and data on new symptoms could 
not be obtained for one patient.
All the patients received one or several re-interventions. Amputations 
were performed three to ten months after the index revascularization 
procedure.
In-depth  
medical  
chart review 
n = 109 
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Table 3. 
Baseline characteristics of all patients who underwent invasive treatment for in-
termittent claudication (2008–2012) and for the patients with major amputation 
following revascularization
Characteristics
Revascularized IC 
(n = 5,860)
Amputated  
after < 1 year
(n = 9)
Amputated
after > 1 year
(n = 27)
Male sex 3,196 (55%) 7 (78%) 18 (67%)
Median age (range) 70 (50–96) 70 (65–82) 68 (52–85)
INVASIVE METHOD      
Endovascular therapy 4,676 (80%) 3 (33%) 19 (70%)
Open surgery 1,033 (17%) 3 (33%) 8 (30%)  
Hybrid surgery 151 (3%) 3 (33%) 0
SMOKING      
Active 355 1 3
Former 1,604 6 20
Non-smoker 456 2 4
Missing data 3,445 0 0
     
Time to onset of  
new symptoms NA
1 day to 2 months
(1 not known)
1 day to 23 months      
(12 not known)
Time to major  
amputation, months NA
3–10                          
(1 not known) 14–61
NA = Not Applicable
In the group who underwent amputation after more than one year 
after revascularization, two out of the 27 had had instant failure of 
the index procedure with immediate re-intervention, and underwent 
amputation after 14 and 18 months. 
The risk of procedure-related major amputation one year after 
revascularization for IC was small, but existing. 
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6.2 Study II
 
From March 2010 to November 2012, 464 patients aged less than 
80 years were admitted to the vascular surgery out-patient clinic for 
suspected intermittent claudication and screened for inclusion, where-
as 338 patients had a confirmed diagnosis of IC. 65 patients had very 
mild symptoms and/or severe comorbidity. 52 patients had very severe 
symptoms and invasive treatment was considered mandatory (main 
criteria: according to protocol, inability to work).
One patient weighed more than 120 kg (which was the maximum 
weight for the treadmill), 2 patients had had two or more failed ipsilat-
eral vascular interventions, and 13 patients did not speak Swedish. Af-
ter applying the inclusion and exclusion criteria, 205 were still eligible 
for the trial. One patient was excluded due to the need for revascular-
ization below the tibio-peroneal trunk and 48 patients declined partic-
ipation in the study. The remining 158 patients were included. Thus, 
77% of all eligible patients were included (47% of all patients with 
established intermittent claudication referred to the out-patient ward). 
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Figure 6. 
Flow chart of enrolment in the Invasive Revascularization or Not in Intermittent 
Claudication (IRONIC) trial.
Enrolment
464 patients < 80 years  
admitted to the vascular surgery 
outpatient clinic for suspected  
intermittent claudication
338 patients < 80 years with  
intermittent claudication
221 patients
205 eligible patients
158 subjects with intermittent  
claudication randomized
Other diagnosis n=126
(not intermittent  
claudication)
Very mild symptoms and/or 
severe comorbidity n=65
Very severe symptoms, in-
vasive treatment considered 
mandatory n=52
Weight >120 kg n=1
Two or more failed ipsilateral 
vascular interventions n=2
Not swedish speaking n=13
Need for open revasculari-
zation below tibioperoneal 
trunk n=1
No consent n=46
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Age, years*
Sex ratio (M : F)
Smoking habits
   Smoker
   Ex-smoker
   Never smoked
Diabetes mellitus 
BMI, kg/m2*
Duration of symptoms, years
   < 1
   1–2
   > 2 
Ankle: brachial pressure index*
Femoral pulse
   Normal
   Reduced
   Absent
Lesions on duplex ultrasonography
   Aorto-iliac 
   Femoro-popliteal 
   Infra-popliteal 
Intermittent claudication treadmill distance, m*
Maximal treadmill distance, m*
Serum haemoglobin, g/l*
Serum cholesterol, mmol/l*
Serum triglycerides, mmol/l*
Serum creatinine, mmol/l*
Kidney failure (serum creatinine > 170 mmol/l) 
Angina pectoris
Previous myocardial infarction
Cerebrovascular disease 
Chronic pulmonary disease
Type of index procedure (70 patients) 
   Aorto-iliac, endovascular
   Aorto-iliac, open
   Femoro-popliteal, endovascular
   Femoro-popliteal, open
   Infra-popliteal, endovascular
   Infra-popliteal, open
68(7)
41 : 38
24 (30)
22 (28)
33 (42)
14 (18)
26 (5)
 17 (22)
20 (25)
42 (53)
0.73 (0.17)
41 (52)
23 (29)
15 (19)
32 (41)
63 (80)
2 (3)
78 (59)
189 (106)
135 (13)
4.9 (1.1)
1.5 (1.0)
81 (26)
3 (4)
7 (9)
12 (15)
7 (9)
10 (13)
24
4
32
13
1
1
Invasive 
group
(n = 79)
Non-invasive 
group
(n = 79)
68(6)
42 : 37
22 (28)
32 (40)
25 (32)
16 (20)
26 (4)
10 (13)
39 (49)
30 (38)
0.74 (0.14)
44 (56)
21 (27)
14 (18)
30 (38)
62 (78)
2 (3)
87 (60)
194 (103)
137 (13)
4.7 (1.2)
1.5 (1.0)
89 (30)
1 (1)
10 (13)
10 (13)
9 (11)
5 (6)
 
 
 
 
 
 
Table 4. 
Baseline demographic data and risk 
factor profiles, by treatment group
Values in parentheses are percentages unless otherwise indicated.
*Values are mean (SD).
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Of the 158 patients, 79 were randomized to each group. In the invasive 
group, 70 of the 79 patients received invasive treatment. Thirteen of 
the 70 patients needed and received 22 re-interventions. In the non-in-
vasive group, 6 out of 79 underwent invasive procedure due to worsen-
ing of symptoms.  
Follow-up analysis included 71 patients in the revascularization group 
and 68 patients in the non-invasive group. 
The invasive treatment strategy had an improved HRQoL compared 
to the non-invasive strategy after two years of follow-up, with a mean 
gain in QALY of 0.16 per patient.
The mean cost per patient was more than four times higher in the 
revascularization group, with a cost difference of €6,379. The incre-
mental cost-effectiveness ratio  (ICER) was €42,881 per QALY in a 
ITT analysis. 
This was within the accepted threshold according to Swedish National 
Guidelines75, but above that in the UK National Institute for Health 
and Care Excellence guidelines.
In a complete case,“as treated” analysis, the cost difference was higher 
with a difference of €7,973 and with a higher mean in QALY of 0.19. 
giving an ICER of €42,704, which was very similar to the ICER from 
the ITT analysis.   
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Values in parentheses are 95% confidence intervals. QALY, quality-adjusted 
life year; ITT, intention-to-treat; *P < 0.010, †P < 0.001 (t-test).
Invasive 
group
Non-invasive 
group
Difference
Cost-effectiveness 
ratio, € per QALY
8,280
(6,421, 10,339)
1,901
(732, 3,071)
6,379
(4,229, 8,728)*
42,881
ITT
Mean cost per patient, € Mean QALYs per patient
9,201
(7585, 10,816)
1,228
(−319, 2,775)
7,973
(5,739, 10,206)
42,704
As treated
1.41
(1.29, 1.46)
1.25
(1.17, 1.34)
0.16
(0.06, 0.24)†
ITT
1.43
(1.36, 1.50)
1.24
(1.18, 1.31)
0.19
(0.09, 0.28)*
As treated
Table 5. 
Cost comparison between Invasive and Non-invasive group
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Figure 7.
Cost-effectiveness acceptability curve (intention-to-treat analysis).
Uncertainty analysis was performed and expressed as a cost-effective-
ness acceptability curve showing the probability of invasive treatment 
being cost-effective relative to non-invasive treatment at different 
thresholds of willingness to pay.
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6.3 Study III
At five-year follow-up, 13 deaths in the invasive group and seven in 
the non-invasive group had occurred. Three patients in each group had 
progression to CLTI and one patient in the non-invasive group had a 
major amputation after unsuccessful revascularization procedures. 
Invasive procedures during the five-year study period
In the invasive group, 72 of the 79 patients had an invasive treatment 
during the five-year study period. Of the patients who were not treat-
ed  invasively, six had improved while waiting for revascularization 
and one patient had a non-significant stenosis on digital subtraction 
angiography.
Twenty-two patients required more than one invasive treatment. In 
total, the invasive group had 114 procedures, of which 82 were endo-
vascular, two were hybrid, and 30 were open vascular procedures.
In the non-invasive group, 20 of the 79 patients had invasive treatment 
during the five-year study period. Seven patients required more than 
one procedure. Altogether, 33 procedures were performed,  of which 
17 were endovascular, three were hybrid, and 13 were open vascular 
procedures. 
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Assessed for eligibility (n = 338)
Randomized (n = 158)
Excluded  (n = 180)
• Did not meet inclusion criteria (n = 134)
• Declined participation (n = 46)
Allocated to non-invasive group (n = 79)
• Underwent revascularization (n = 20)
• > 1 procedure (n = 7)
• 1 procedure (n = 13)
Allocated to invasive group (n = 79)
• Underwent revascularization (n = 72)
• > 1 procedure (n = 22)
• 1 procedure (n = 50)
Lost to follow up of  
HRQoL endpoint (n =21)
Death (n = 7)
Severe cardiac disease (n = 2)
Sepsis (n = 1)
Cause not verified (n = 1)
Cancer (n = 2)
Stroke (n = 1)
Withdrew consent (n = 7)
Amputation (n = 1)
Moved (n = 2) 
Stroke (n = 1)
Hip fracture (n = 1)
Critical ischemia (n = 1)
Additional loss to follow-up  
for treadmill testing
Withdrew consent (n = 9)
Lost to follow up of  
HRQoL endpoint (n = 21)
Death (n = 13) 
Severe cardiac disease (n = 7) 
Cancer (n = 3) 
Stroke (n = 1)  
Cause not verified (n = 2)
Withdrew consent (n = 3)
Moved (n = 1) 
Kidney failure (n = 1)
Stroke (n = 1)
Cancer (n = 1)
Heart failure (n = 1) 
Additional loss to follow-up for 
treadmill testing 
Withdraw consent (n = 15)
Cancer (n = 1)
Follow-up 
5-year
Analyzed primary  
endpoint HRQoL (n = 58)
Analyzed treadmill testing (n = 49)
Analyzed primary  
endpoint HRQoL (n = 58)
Analyzed treadmill testing (n = 42)
Analysis
Figure 8.
The IRONIC trial 
flow diagram
Allocation
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Primary outcome
For the primary outcome, HRQoL data were available for 116 patients 
(73% of all  study patients and 84% of all patients who were alive) at 
five-year follow-up (Figure 1). 
The mean follow-up time was 5.2 years (range 4.8–6.1). The major 
reason for non-participation was death (n = 20).
Concerning changes between the groups compared to baseline, no 
differences were observed for the SF-36 sum and domain scores, except 
for the SF-36 “role emotional” domain score, which had a greater 
improvement in the non-revascularization group both in the ITT 
analysis and the per-protocol analysis.
Regarding changes within the groups compared to baseline, both 
groups improved on the SF-36 physical component summary  
(p < 0.05) and on several domain scores:
Invasive group: physical functioning, p < 0.05,  
and bodily pain, p < 0.01;  
Non-invasive group: physical functioning, p < 0.01,  
bodily pain, p <0.01, and role emotional, p < 0.01). 
In both groups, however, all the effects sizes for domain and summary 
scores were trivial, small, or moderate. 
Supporting outcomes 
In congruence with the SF-36 results, no significant inter-group differ-
ences for VascuQoL changes were observed (n = 116). The results here 
were also consistent between the ITT analysis and the per-protocol 
analysis.
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Figure 9.
Intent to treat analysis
Spider plot illustrating HRQoL outcomes in intent-to-treat analysis, 
presented as effect sizes (ES) calculated between baseline and 60 months. 
Cohen’s criteria for ES: 0.0-0.2=trivial; 0.2-0.5=small; 0.5-0.8=moderate; 
>0.8=large. 
All differences between invasive + exercise vs exercise patients were non-sig-
nificant except for SF-36 Role emotional domain score with a p-value at 0.013 
(Mann-Whitney U). Data was available and analyzed for 116 patients. 
Invasive group
Non-invasive group
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Figure 10.
Per protocol analysis
Spider plot illustrating HRQoL outcomes in per-protocol analysis, 
presented as effect sizes (ES) calculated between baseline and 60 months.
Cohen’s criteria for ES: 0.0-0.2=trivial; 0.2-0.5=small; 0.5-0.8=moderate; 
>0.8=large. 
All differences between invasive + exercise vs exercise patients were non-sig-
nificant except for SF-36 Role emotional domain score with a p-value at 0.017 
(Mann-Whitney U). Data was available and analyzed for 98 patients.
Invasive group
Non-invasive group
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Walking capacity
Regarding walking capacity, the treadmill test showed no significant in-
ter-group differences in change between baseline to five-year follow-up 
for ICD, or in MWD. 
Regarding changes within the groups, both groups improved signifi-
cantly in ICD but no significant improvement in MWD was observed. 
The invasive group had a (non-significant) deterioration in MWD. 
There was an additional loss of patients in the treadmill test, and data 
were available for 91 patients. 
Figure 11.
Change in walking capacity.
Change in walking capacity measured on a graded treadmill, from baseline to 
five-year follow-up. ICD, intermittent claudication distance; MWD, maximum 
walking distance.
Change in ICD (meters) Change in MWD (meters)
55
14
51
-12
Non-invasive group (n=49)
Invasive group (n=42)
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Cost-effectiveness analysis 
Cost-effectiveness analysis was performed on an ITT basis for the com-
plete cases including deaths (n = 130). 
The changes in health status assessed with QALYs and adjusted for 
difference in baseline gave a non-significant difference of −0.10  for 
the invasive group. The cost in the complete case analysis was almost 
double for the invasive group, with a difference of $6,133.
Thus, the invasive treatment was dominated (more expensive and 
worse health outcome). 
In the multiple imputation analysis, the mean gain in QALYs for the 
invasive group was 0.001 with a cost difference of $5,849, which gave 
a cost-effectiveness result of $5,503,448 per QALY.
 
Thus, the MI analysis gave an ICER where invasive treatment was 
not cost-effective compared to non-invasive treatment, irrespective of 
which willingness-to-pay threshold applied.
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Non-invasive
group
invasive 
group
Difference
ICER 
incremental cost-effec-
tiveness ratio.
6,965
(2,975–10,955)
13,098
(9,713–16,482)
6,133
(972–11,292)
Cost per patient
Invasive treatment dominated 
(more expensive and worse 
health outcome)
Cost per patient
$5,503,448 per QALY
Full sample results based on  
multiple imputation (n = 158)
Complete case analysis 
including deaths (n = 130)
3.04
(2.81–3.26)
2.88
(2.59–3.16)
−0.10*
(−0.45 to 0.25)
QALYs QALYs
-
-
5,849
(1,202-10,496)
-
-
0.001
(−0.32 to 0.32)
Table 6.
Mean cost per patient, in USD, and QALYs (95% CI) in the non-invasive and inva-
sive groups
* Due to adjustment for the difference in baseline QALY weight (lower for 
invasive group), the difference in the CCA analysis results is a slightly different 
outcome compared to the difference in raw values. In the full sample, estimates 
of the difference between groups were based on multiple imputed QALYs (the 
combined result was based on Rubin’s rules).
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Uncertainty analysis was performed with non-parametric boot-
strap-ping (1,000 bootstraps). The results are shown in both a cost-ef-
fectiveness scatter plot and a cost-effectiveness acceptability curve 
based on the multiple imputation analysis.
Figure 12. 
Cost-effectiveness 
plane based on 
multiple imputation. 
Each dot represents 
one bootstrapped 
result (in total, 
1000).
Figure 13.  
Cost-effectiveness 
acceptability curve 
based on multiple 
imputation.
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6.4 Study IV
From 2010 to 2015, 310 patients were assessed for eligibility and 100 
patients were enrolled in the study.  An intention-to-treat, complete 
case analysis was performed for the patients with sufficiently answered 
EQ-5D data and complete cost data (n = 65: stent group, n = 36, con-
trol group, n = 29). One EQ-5D response was missing for 14 of the 65 
patients (stent, 5, control, 9) and linear extrapolation was performed in 
these cases. A table with baseline characteristics of these patients was 
drawn up. 
Age
Male
Female
ABI
WD
Duration IC (months)
Smoking, active
Smoking, former
Smoking, never
LDL
B-glc
BP syst
BP diast
Creatinine
Lesion length
Occl
Stenosis
Degree of stenosis
No. crural vessels
70.8(5.3)
15
21
0.60(0.12)
167(88)
29(29)
4
21
11
2.5(0.9)
7.3(3.0)
154(22)
80(11)
86(25)
144(94)
23
12
95.2(10)
2.4(0.6)
0.79
0.324
0.427
0.263
0.608
0.066
0.962
0.098
0.182
0.347
0.686
0.05
0.382
0.382
0.291
0.982
Stent (SD)
Region Skåne
    (n = 65)
Control (SD) p-value
70.5(4.8)
16
13
0.62(0.18)
192(96)
34(44)
5
22
2
2.5(0.7)
6.1(1.2)
145(23)
78(8)
83(19)
96(100)
21
8
97.4(4)
2.5(0.7)
Table 7. 
Baseline demographic data and lesion characteristics (by treatment group) for 
the patients in the complete case analysis (n = 65).
Mean (SD) or n (%).
B, blood; BP, blood pressure; IC, intermittent claudication; LDL, low-density  
protein; ABI, ankle-pressure index.
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The mean gain in QALYs was 0.24 for the invasive group compared to 
the non-invasive group, after adjustment for the difference in baseline 
QALY weight.
The cost was three times higher in the invasive group, with a mean 
difference of SEK 81,216, resulting in an ICER of 332,112 SEK/QALY.
To investigate the effects of missing QALY weight data, an additional 
intention-to-treat, multiple imputation analysis was performed for the 
patients with complete cost data. In this analysis, two patients were 
excluded due to the total absence of EQ-5D responses.  In this MI 
analysis (n = 75: stent, 40, control, 35) where the missing QALY weight 
was imputed, the difference between the invasive group and the non-in-
vasive group was higher, with a mean QALY per patient of 0.3999.   
In the MI analysis, the difference in cost was  SEK 87,700. This result-
ed in a lower ICER with a value of 219,357 SEK per QALY
Stent treatment
+ exercise advice
Exercise  
advice alone
Difference
Cost-effective-
ness ratio  
(SEK per QALY)
115,757
(92,439, 139,075)
34,541
(22,889, 46,193)
81,216
(53,653, 108,779)
1.31
(1.18, 1.44)
0.97
(0,78, 1.17)
0.24*
(0.05, 0,43)
-
-
87,700
(61,430, 113,971)
-
-
0.40*
(0.03, 0.77)
ITT CCA 
(n = 65)
ITT CCA 
(n = 65)
ITT Multiple 
imputation
(n = 75)
ITT Multiple 
imputation
(n = 75)
332,112 219,357
Mean QALYs per patientMean cost per patient (SEK)
Table 8.
Costs of stent treatment + exercise advice compared to exercise advice alone
Values in parentheses are 95% confidence intervals. ITT, intention-to-treat; CCA, 
complete case analysis. *Due to adjustment for the difference in baseline QALY 
weight, the outcome for the difference in mean QALYs was slightly different 
from the difference in raw values.
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Uncertainty analysis was performed with non-parametric bootstrap-
ping (1,000 bootstraps) for a complete case, ITT analysis. The results 
were expressed in a cost-effectiveness plane where they were mainly 
centred in the northeast quadrant, whereby invasive treatment was 
more expensive but also provided a better  health outcome compared 
to non-invasive treatment. The results was also expressed in a CEAC 
to show the probability of being cost-effective at different thresholds 
regarding willingness to pay for QALY.
Figure 14. 
Cost-effectiveness 
plane based on in-
tention to treat anal-
ysis in the complete 
case analysis (n=65). 
Each dot represents 
one bootstrapped 
result (in total, 
1000).
Figure 15. 
Cost-effectiveness 
acceptability curve 
based on intention 
to treat analysis in 
the complete case 
analysis (n=65).
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7.1 Study I
This retrospective cohort study included IC patients who were treated 
invasively between 2008 and 2012. To our knowledge, no major chang-
es in technological treatment approaches for these patients have been 
adopted since 2012.
Large registries are suitable for capturing rare but important events, such 
as major amputation after a revascularization procedure for IC. In-depth 
analysis of the medical records of the amputated patients did, however, 
reveal a sizeable number of misclassifications concerning the reported 
revascularization indication in the Swedvasc registry. If patients are 
wrongly classified throughout the entire register, this could possibly affect 
the results of this study, and also of all other studies that use similar data 
from this registry. In clinical reality, patient symptomatology can make 
it difficult to clearly distinguish between very severe IC and CLTI, which 
may explain some of the misclassifications. There have been evaluations 
of the Swedvasc registry. Troeng et al.88 investigated the external validity 
only, however, and not whether the specific indications for the bypasses 
were correct; similarly, Venermo et al.83 validated only the external and 
internal validity for the carotid and aortic registrational work flows.
Discussion and 
limitations
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The definition of a major amputation potentially attributable to a proce-
dure is difficult, since a patient might deteriorate to CLTI due to rapidly 
progressing atherosclerosis – especially if the patient is non-compliant 
regarding advice about lifestyle changes such as medication and cessa-
tion of smoking. Thus, a reasonable arbitrary line was set, within one 
year after the procedure. 
We believe that the one-year time point chosen during follow-up is 
relevant in this particular context, as it was likely to capture patients 
that had been amputated due to short- or medium-term complications 
of the surgical intervention. By limiting the primary follow-up time 
point to one year, but still reporting events during a median follow-up 
period of 3.9 years, we aimed to discriminate between possible pro-
cedure-related limb complications and events that occurred due to 
progression of the atherosclerotic disease.
7.2 Studies II, III, and IV
Randomized controlled trials (RCTs) constitute a key source of a high 
level of evidence. However, they have some limitations. One of the major 
problems is the generalizability. In the IRONIC study, 77% of all eligible 
patients were included and 47% of all patients with confirmed intermit-
tent claudication who were referred to the vascular out-patient ward 
were randomized in the study.
Of the patients who were excluded, 65 had very mild symptoms and/or 
severe comorbidity whereas 52 had very severe IC, as compared to 158 
patients in the whole study. Thus, on the one hand, we were missing the 
possible increase in health-related quality of life that invasive treatment 
might provide for the 52 patients with very severe IC, but on the other 
hand, also the unnecessary revascularization procedures, with the risks 
entailed, that the patients with very mild IC would have been omitted to.
In Study IV, patients were recruited between 2010 and 2015 from seven 
hospitals. Considering the long accrual period and the large number of 
hospitals involved, probably only a small proportion of patients admit-
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ted to the vascular open ward with intermittent claudication, caused by 
a lesion in the SFA, were assessed for the study. This may have impaired 
the generalizability of the study. 
Comparing the patients included in studies II and III with all the patients 
revascularized for IC in Sweden between 2008 and 2012 (n = 5,860) in 
Study I, there were no major differences regarding age or gender. 
There were more active smokers in the IRONIC study than in the cohort 
in Study I, but since there were data missing for the majority of patients 
regarding smoking status in Paper I, we do not know the real proportion 
of active smokers in that cohort.
The majority of index procedures were endovascular in the IRON-
IC study (76 %), as in study I (80%). 
Comparing Papers III and IV with the data by Kumakura et al., who 
investigated 1,107 patients with de novo IC, there was similarity in age 
and smoking habits. Sixty per cent in this cohort were male.
The potential problem of generalizability in RCTs also applies to the 
cost-effectiveness analysis. We chose to conduct the cost-effectiveness 
analysis from a healthcare point of view. We then might have missed 
possible effects on and benefits to productivity. Considering that one of 
the exclusion criteria in the IRONIC study was very severe IC, which 
in most cases precluded the patients from working, these patients were 
already excluded in the analysis. In Study IV, this was not a direct ex-
clusion criterion, but it is unlikely that many patients with difficulties in 
working due to IC would have been included in the study.
Thus, one must emphasize that the cost-effectiveness results in these 
studies are not applicable from a societal standpoint, where invasive 
treatment possibly enables patients to return to work.
 
The mean age at baseline for study patients was 68 in the IRONIC study, 
and 71 (stent group) and 70 (control group) in Study IV.
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Using RCTs for cost-effectiveness analysis has the disadvantage of a 
limited follow-up, such as the two-year limit in Papers II and IV. In a 
clinical study setting, this is often considered to be a long-term fol-
low-up but from a health-economic point of view this may be consid-
ered to be a short time frame. Effects of the treatments may extend 
beyond the time limit of the study, and the costs associated with each 
treatment may continue. Thus, one must interpret the results from such 
studies with caution regarding the real-world effects. It is worth men-
tioning that when Paper II was published, it was the cost-effectiveness 
analysis (comparing invasive treatment and non-invasive treatment 
for IC) alongside a randomized trial with the longest follow-up to be 
performed. Thus, this paper added further knowledge to the field.
A negative aspect of having a longer follow-up time may be the in-
creased risk of missing data. In elderly patient populations, as in the 
studies in this thesis, death will be a factor that affects the results 
during longer-term follow-up. The higher number of deaths in the 
invasive group than in the non-invasive group (13 vs. 7) did of course 
affect the economic analysis. When calculating an ICER in a CCA 
analysis without deceased patients, invasive treatment was no longer 
dominated but invasive treatment was still not cost-effective at any 
willingness-to-pay threshold applied. 
The IRONIC study used in Papers II and III was powered for two-year 
follow-up and an additional loss of patients at five years may have 
affected the results in Study III. It is not clear why the results were 
different from those in earlier reports47, 48, which showed a significant 
benefit from invasive treatment compared to non-invasive treatment. 
As expressed in Paper III, the reason may have been loss of patency for 
invasive treatments during the follow-up, which might have contributed 
to the loss of benefit. The index procedures were guided by the TASC 
II recommendations, and choice of technique was strictly regulated. In 
retrospect, the possible improvement in operative technique that could 
have been considered for the index procedures might have been primary 
stenting of the femoro-popliteal segment instead of angioplasty alone. 
79HENRIK DJERF
However, superior long-term patency of primary stenting compared to 
angioplasty is yet to be proven.
One might consider that necessary lifestyle changes would not be put 
into practice if an early invasive treatment reduced the patient’s moti-
vation to undertake such changes. Other reasons for the loss of benefit 
could be that other concurrent diseases affecting walking capacity and 
HRQoL might have developed during the study. As with the clinical re-
sults, the cost-effectiveness results changed between two- and five-year 
follow-up. When comparing between invasive treatment and non-in-
vasive treatment in an RCT, one might expect that the costs for the 
invasive treatment group could be found at the beginning of the study. 
However, in the IRONIC trial, the invasive group still continued to 
undergo more invasive interventions that generated costs even later on. 
One reflection from a clinical point of view is that it may be  difficult to 
deny the patient a second procedure if the first one fails or if the benefit 
of the procedure starts to fade. With the number of procedures persist-
ing and a loss in HRQoL at five years, the invasive treatment strategy 
was not found to be a cost-effective option.
At baseline in the IRONIC study, there were no significant inter-group 
differences in the SF-36 or in the Vascular Quality of Life questionnaire 
(VascuQoL).  There was a slight – although not significant – difference 
between treatment arms regarding EQ-5D at baseline. EQ-5D at fol-
low-up showed trends similar to the results for SF-36. In Study II, the 
adjustment for difference in baseline QALY weight was not described 
in the paper.
In Study IV, there was also a non-significant difference in EQ-5D at 
baseline in the complete case analysis (p = 0.11). No significant in-
ter-group differences in the SF-36 were found at baseline.
For the cost-effectiveness analysis in Papers II and III, we also 
assessed the outcome with SF-6D (which is derived from SF-36) and 
found no major differences from the results with EQ-5D.
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In Study IV, there were also greater costs (about 50% increase) at two-
year follow-up, both for the non-invasive group and for the non-inva-
sive group, compared to the IRONIC study in Paper II. This difference 
can be partly explained by the study setting in the IRONIC trial, with 
follow-up visits by a nurse, whereas the patients had follow-up visits 
by doctors in Study IV.
The RSVD system in Paper IV is not as precise as the cost-per-patient 
system used in the IRONIC trial. The cost-per-patient system in the 
IRONIC study enabled diagnostic procedures and costs for each oper-
ative procedure to be pinpointed to an individual patient whereas the 
RSVD system cannot pinpoint each diagnostic procedure or a price per 
minute for the procedures. It is based on a system where the accumu-
lated costs for each economic section (e.g. the open ward) are divided 
by the calculated production for that economic section. The patient’s 
diagnosis will thereafter render a specific cost for each out-patient or 
in-patient entry.
Health-economic evaluations that extract costs from hospital regis-
tries are always dependent on the costs that have been apportioned for 
each item. When registries change over time, the allocation of costs for 
different items can change, affecting the results.
Compared to the multi-centre study in Paper IV, the IRONIC study 
(Papers II and III) was a single-centre study and the operative results in 
this study were therefore dependent on the operative expertise at one 
single hospital. The Vascular Department at Sahlgrenska University 
Hospital is a large vascular centre that is well acquainted with both 
open surgical and endovascular treatment.
When performing an RCT, the optimal arrangement is to conceal the 
real treatment from both the healthcare personnel and the patients. 
This is difficult to accomplish when comparing a surgical intervention 
with conservative management, and one must consider that a placebo 
effect would be introduced with invasive treatment, at least for the 
initial follow-up. To this end, the results from the double-blinded ran-
domized controlled ORBITA study89, where patients with stable angina 
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pectoris were randomized to either percutaneous coronary intervention 
or a placebo intervention, highlight this problem. In this study, there 
was no significant difference in exercise time between PCI and the 
placebo intervention. 
For the non-invasively treated patients in the IRONIC study, enrolling 
patients in a study with a more rigorous follow-up scheme compared 
to the real clinical situation might give the study participants increased 
motivation compared to patients in a real-world clinic, a feature that 
may introduce bias. However, as the same follow-up scheme was pro-
vided in both treatment arms, the effect of this phenomenon would be 
expected to be limited. 
In clinical trials, it is difficult to include all possible comparative treat-
ments.
Regarding patient benefit and cost-effectiveness of invasive and non-in-
vasive treatment, the studies in Papers II, III, and IV all compared in-
vasive treatment with the most common non-invasive treatment used, 
which was exercise advice. Other treatment arms would also have been 
possible, for example a more intense home-based structured exercise 
programme or a hospital-based supervised exercise programme, but 
such treatment arms were not included in any of the studies. It remains 
unclear whether the benefit of invasive treatment in Studies II and IV 
would still yield results that would be below the willingness-to-pay 
threshold according to Swedish national guidelines, if the non-invasive 
comparative option had been a supervised or home-based exercise pro-
gramme. In the setting of a shorter follow-up period, Markov model-
ling by Bermingham et al. indicated that SET was a more cost-effective 
option than unsupervised exercise90.
Supervised or home-based exercise programmes are interesting alterna-
tives, both as separate alternatives and as adjuncts to invasive treat-
ment, to improve long-term HRQoL and also as long-term cost-effec-
tive treatment options. One must, however, take into account the costs 
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associated with the development and maintenance of a hospital-based 
supervised exercise programme or a home-based exercise programme.
One word of caution when interpreting results from studies with SET: 
some studies allow patients allocated to  SET to perform the exercise 
on the treadmill, and then use treadmill testing as endpoint. Since there 
is a well-known “learning effect” with exercise performance on tread-
mills, there is bias that might blur the result56, 91, 92. 
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Invasive treatment for IC had a low but real risk of major amputation 
within the first post-procedural year. 
A liberal invasive treatment strategy for IC increased costs after  two 
years of follow-up, but since HRQoL also increased, the cost-effec-
tiveness results were within the acceptable threshold according to the 
Swedish national guidelines regarding willingness to pay.
The clinical  benefit of a liberal revascularization strategy observed at 
two years was lost at five years, and in the long term was not a cost-ef-
fective option compared to exercise alone.
Conclusion
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The main consideration when dealing with patients with IC is that the 
clinician has a patient presenting with a peripheral problem while the 
factors that have developed this disease have also led to an increased 
risk of a major cardiovascular event and a higher mortality risk rela-
tive to the general population. The patients are not often aware of this 
aspect. Thus, the treatment of the localized peripheral disease must 
always be combined with treatment of the increased risk of cardio-
vascular events, and we must make the patient aware of the necessary 
changes in lifestyle that are needed. 
Today, invasive procedures are an established method for reducing 
lower limb symptoms in IC.
     
The randomized studies in this thesis were all front-line research in-
vestigating clinical outcomes and cost-effectiveness with two and five 
years of follow-up. However, more studies are needed to clearly define 
the role of invasive treatments in reducing lower limb symptoms.
From a cost-effectiveness point of view, it is interesting if the availabil-
ity of a home-based or supervised exercise programme can reduce the 
number of invasive procedures in the long term. 
Future work
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In the five-year follow-up  by Mazari60, the adding of SET to endovas-
cular therapy reduced the number of re-interventions in the long term, 
which might be beneficial from a cost-effectiveness standpoint.  
More long-term studies are also needed to investigate the optimal exer-
cise programme that may provide long-term compliance and long-last-
ing benefit for IC patients.
 
Future studies might consider having the option of physical activity 
as an extra measure. One meta-analysis concluded that structured 
exercise programmes increased physical activity in the short term (and 
endovascular procedures did not), which could possibly lead to addi-
tional benefits regarding the risk of cardiovascular events18, 93. 
Invasive treatment is constantly developing, and new endovascular 
technology might provide better long-term patency for IC procedures.
More precise targeting of patients might be possible in the future, with 
more advanced imaging to select which patients are likely to develop 
restenosis after invasive procedures94.
Overall, further studies, preferably large randomized multi-centre stud-
ies, are needed to determine when to choose invasive treatment instead 
of non-invasive treatment, and to provide information on which pro-
cedures can provide long-lasting benefit in HRQoL and at a cost that is 
acceptable to the healthcare provider. 
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Claudicatio intermittens, även kallad fönstertittarsjuka, orsakas av 
otillräcklig blodtillförsel till benens muskler på grund av arterosklero-
tiska förträngningar. Vid ansträngning leder detta till mjölksyrautveck-
ling och smärtor i benen som i sin tur resulterar i nedsatt gångförmåga 
och livskvalitet. Dessa bensymptom kan lindras både av gångträning 
och operationer. 
Resursåtgången för denna grupp förväntas öka på grund av en 
åldrande befolkning. Långtidseffekten och kostnadseffektivitet av  
operativ behandling är dock bristfälligt studerad. 
Den övergripande målsättningen med detta avhandlingsprojekt var 
att undersöka kliniska resultat och kostnadseffektivitet för operativ 
behandling vid claudicatio intermittens jämfört med gångträning.
Den mest fruktade komplikationen vid operation för claudicatio 
intermittens är att operationen misslyckas och att blodflödet till benet 
istället försämras, vilket i värsta fall kan leda till amputation. Vi fann 
att denna risk var låg men att den trots allt existerade och varje beslut 
om operativ behandling måste därför noggrant övervägas. 
Efter två års uppföljning var operativ behandling dyrare jämfört 
med gångträning, men på en acceptabel kostnadsnivå jämfört med 
nationella svenska riktlinjer. 
På lång sikt (fem års uppföljning), såg vi dock att den tidigare 
observerade nyttan vid två år, med operativ behandling (jämfört med 
enbart gångträning), inte längre kunde påvisas. Operativ behandling 
var inte heller ett kostnadseffektivt alternativ jämfört med gångträning 
efter fem års uppföljning.
Populärvetenskaplig  
sammanfattning 
på svenska
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